ARCB vs PSIX

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

PSIX exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 3.15). While the company shows aggressive revenue growth (32.5%) and an extraordinary ROE (93.49%), there is a concerning divergence as YoY earnings growth has plummeted by 31.6%. The stock is currently trading at a significant premium to its Graham Number ($29.35) and Intrinsic Value ($34.58), suggesting the market has priced in substantial future growth that is not yet reflected in the bottom-line earnings trend.